The New England journal of medicine
Audio Summaries

Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies

May 6, 2026

The authors aimed to determine whether a higher dose of oral ivermectin (400 μg/kg) combined with 5% permethrin cream is more effective than the standard dose (200 μg/kg) in curing severe scabies. In a randomized trial involving 132 adults, they found no significant difference in cure rates between the two dosing regimens, with 75% in the higher-dose group and 82% in the standard-dose group achieving cure. The study concluded that the higher dose of ivermectin does not provide superior efficacy compared to the standard dose when used with permethrin cream.

Cerebral Amyloid Angiopathy

May 6, 2026

This article by Steven M. Greenberg examines cerebral amyloid angiopathy (CAA), a significant cause of hemorrhagic stroke and cognitive decline, and seeks to address the challenges in diagnosing and managing the condition. The authors highlight the need for improved risk prediction tools, early diagnostic markers, and potential therapeutic targets to better manage the high risk of recurrent strokes associated with CAA. Ongoing research aims to enhance understanding of the disease's pathology and inform treatment strategies.

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults

May 6, 2026

The authors aimed to evaluate the efficacy and safety of an investigational mRNA-based seasonal influenza vaccine, mRNA-1010, in adults aged 50 and older. The phase 3 trial demonstrated that mRNA-1010 was superior to a standard-dose comparator vaccine in preventing RT-PCR-confirmed influenza-like illness, with a relative vaccine efficacy of 26.6%. While mRNA-1010 was associated with more frequent mild to moderate adverse reactions, serious adverse events were similar between the two groups.

Daraxonrasib in Previously Treated Advanced <em>RAS</em>-Mutated Pancreatic Cancer

May 6, 2026

This study investigates the safety and efficacy of daraxonrasib, a multiselective RAS inhibitor, in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). The results indicate that while 96% of patients experienced treatment-related adverse events, daraxonrasib demonstrated antitumor activity, with objective response rates of 35% in patients with RAS G12 mutations and 29% in those with other RAS mutations. The findings suggest potential benefits of daraxonrasib in this challenging patient population, warranting further investigation.

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors

Apr 29, 2026

The authors aimed to evaluate the efficacy of Mim8, a bispecific antibody, for bleeding prophylaxis in patients with hemophilia A, both with and without factor VIII inhibitors. In a phase 3 trial, they found that Mim8 significantly reduced the annualized rate of treated bleeding events compared to on-demand treatment and standard clotting factor concentrate prophylaxis. The study concluded that Mim8 prophylaxis is a superior option for managing bleeding in these patients.

Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples

Apr 29, 2026

The authors aimed to evaluate the diagnostic accuracy and usability of the MiniDock MTB test for detecting pulmonary tuberculosis using swab samples in various outpatient centers. Their study found that MiniDock MTB demonstrated high sensitivity and specificity, meeting World Health Organization targets for tuberculosis diagnostics, and showed good usability across diverse clinical settings. The results suggest that MiniDock MTB could be a valuable tool for improving tuberculosis detection in peripheral health centers.

Barrett's Esophagus

Apr 29, 2026

The authors investigate the challenges associated with diagnosing Barrett's esophagus, a condition linked to chronic acid and bile reflux that increases the risk of esophageal adenocarcinoma. They emphasize the importance of endoscopic and histopathological criteria for diagnosis and advocate for ongoing surveillance to detect malignant progression early, highlighting the potential benefits of clinical trial participation to enhance detection and management strategies.

Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation

Apr 27, 2026

This study investigates whether pulsed field ablation (PFA) is a more effective initial treatment for patients with persistent atrial fibrillation compared to traditional antiarrhythmic drug therapy. The results indicate that PFA significantly reduces the risk of recurrence of atrial arrhythmias at 12 months, with a treatment success rate of 56% in the PFA group versus 30% in the antiarrhythmic-drug group. Additionally, the safety profile of PFA was comparable to that of antiarrhythmic drugs, suggesting PFA may be a preferable first-line therapy.

Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock

Apr 24, 2026

This study investigates whether balanced crystalloid fluid provides better outcomes than 0.9% saline in children with septic shock. The results show no significant difference in major adverse kidney events between the two fluid resuscitation methods, suggesting that both options are similarly effective for this patient population. Additionally, the balanced fluid group experienced lower rates of hyperchloremia compared to the saline group.

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients

Apr 22, 2026

The authors aimed to evaluate the effectiveness of oral nirmatrelvir-ritonavir in reducing hospitalization or death among vaccinated higher-risk outpatients with SARS-CoV-2 infection. In two open-label trials, the results indicated no significant reduction in these outcomes for participants receiving nirmatrelvir-ritonavir compared to usual care alone. Additionally, while the treatment reduced viral load, serious adverse events were reported, highlighting the need for further investigation.